Clinical Trial Update: Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial MK-3475-905/KEYNOTE-905/EV-303 is testing perioperative pembrolizumab with cystectomy, with or without enfortumab vedotin, versus cystect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Padcev (enfortumab vedotin) (enfortumab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urinary Bladder Cancer, Muscle-invasive | Phase 3 | Status: ACTIVE_NOT_RECRUITING